Apnimed (APMD) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apnimed is the larger company by market cap ($669.8 million vs $648.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | SGMT |
|---|---|---|
| Share price | $16.09 | $9.08 |
| Market cap | $669.84M | $648.02M |
| 1-day change | -6.70% | -5.61% |
| YTD return | — | +53.38% |
| 1-year return | — | +36.13% |
| P/E ratio (TTM) | 1.21 | — |
| EPS (TTM) | $13.34 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-51.04M |
| 52-week high | $35.29 | $11.45 |
| 52-week low | $13.88 | $4.50 |
| Distance from 52-week high | -54.41% | -20.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +210.75% | +200.33% |
| Average volume | 458.58K | 1.23M |
| Shares outstanding | 41.63M | 71.37M |
| Employees | 112 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
APMD vs SGMT FAQ
Which is bigger, Apnimed or Sagimet Biosciences Series A?
Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $648.02M for Sagimet Biosciences Series A (SGMT).
Are Apnimed and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.